ALLK: Allakos Inc. Stock

by  •  • Comments Off on ALLK: Allakos Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 88.75
Enterprise Value ($M) 22.31
Book Value ($M) 168.82
Book Value / Share 1.92
Price / Book 0.53
NCAV ($M) 105.10
NCAV / Share 1.19
Price / NCAV 0.84

Profitability (mra)
Return on Invested Capital (ROIC) -0.88
Return on Assets (ROA) -0.53
Return on Equity (ROE) -0.66

Liquidity (mrq)
Quick Ratio 4.92
Current Ratio 4.92

Balance Sheet (mrq) ($M)
Current Assets 179.89
Assets 243.61
Liabilities 74.79
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -196.06
Net Income -185.70
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -116.48
Cash from Investing 93.17
Cash from Financing 2.53

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Logos Global Management LP 3.30 -45.15
02-14 13G/A Deep Track Capital, LP 2.87 -49.79
02-14 13G/A Citadel Advisors Llc 3.80
02-12 13G Price T Rowe Associates Inc /md/ 9.10
02-02 13D/A RiverVest Venture Fund III, L.P. 0.20 -97.82
01-29 13G BlackRock Inc. 5.80 90.51
01-18 13G/A Biotechnology Value Fund L P 9.80 70.81
08-18 13D/A Alta Partners VIII, L.P. 3.50 -64.97
2023-04-17 13G/A Frazier Life Sciences Public Fund, L.P. 0.50 -91.81

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 251,391 399,423 62.94
2024-04-25 93,755 396,845 23.63
2024-04-24 52,965 60,569 87.45
2024-04-23 59,129 80,706 73.26

(click for more detail)

Similar Companies
AKRO – Akero Therapeutics, Inc. ALEC – Alector, Inc.
ALKS – Alkermes plc ALLO – Allogene Therapeutics, Inc.
ALNY – Alnylam Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io